Post-NDC primaries, aspirants blame Peter Obi and Rabiu Kwankwaso. Leadership expert Kalu Okoronkwo examines the real ...
Milestone Pharmaceuticals Inc. is a strong buy after a 37% drop post-Cardamyst FDA approval. Click for this updated look at ...